These findings also give us some hints that the development of CXCL1 and CXCR2 inhibitors based on gut microbiota is expected to alleviate NEC symptoms, and reduce the risk of HIBI complication in infants with NEC, by blocking inflammatory mediators and inhibiting the migration of peripheral neutrophils to the central nervous system, but human-based in vitro and in vivo experiments are still urgently needed. The gene discussed is CXCL1; the disease is necrotizing enterocolitis.